Impact BioMedical Valuation
| IBO Stock | USD 0.51 0.02 4.08% |
Impact BioMedical is overvalued. Impact BioMedical retains a regular Real Value of $0.44 per share. The prevalent price of the firm is $0.51. Our model calculates the value of Impact BioMedical from evaluating the firm fundamentals such as Return On Asset of -0.0768, return on equity of -3.47, and Shares Outstanding of 104.62 M as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Impact BioMedical's valuation include:
Price Book 1.2428 | Enterprise Value | Enterprise Value Ebitda 4.7203 | Price Sales 2.1 K | Enterprise Value Revenue 3 K |
Overvalued
Today
Please note that Impact BioMedical's price fluctuation is out of control at this time. Calculation of the real value of Impact BioMedical is based on 3 months time horizon. Increasing Impact BioMedical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Impact BioMedical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Impact Stock. However, Impact BioMedical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.51 | Real 0.44 | Hype 0.51 | Naive 0.46 |
The intrinsic value of Impact BioMedical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Impact BioMedical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Impact BioMedical helps investors to forecast how Impact stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Impact BioMedical more accurately as focusing exclusively on Impact BioMedical's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Impact BioMedical's intrinsic value based on its ongoing forecasts of Impact BioMedical's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Impact BioMedical's closest peers.
Impact BioMedical Cash |
|
Impact BioMedical Total Value Analysis
Impact BioMedical is currently forecasted to have company total value of 75.76 M with market capitalization of 52.83 M, debt of 8.88 M, and cash on hands of 2 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Impact BioMedical fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
75.76 M | 52.83 M | 8.88 M | 2 M |
Impact BioMedical Investor Information
The company has price-to-book (P/B) ratio of 1.24. Some equities with similar Price to Book (P/B) outperform the market in the long run. Impact BioMedical recorded a loss per share of 3.94. The entity had not issued any dividends in recent years. Impact BioMedical may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.19 | 0.21 |
|
|
Impact BioMedical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Impact BioMedical has an asset utilization ratio of 11.49 percent. This suggests that the Company is making $0.11 for each dollar of assets. An increasing asset utilization means that Impact BioMedical is more efficient with each dollar of assets it utilizes for everyday operations.Impact BioMedical Ownership Allocation
Impact BioMedical has a total of 104.62 Million outstanding shares. Roughly 98.89 (percent) of Impact BioMedical outstanding shares are held by general public with 0.6 % owned by insiders and only 0.51 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Impact BioMedical Profitability Analysis
The company reported the last year's revenue of 2.33 M. Reported Net Loss for the year was (35.53 M) with profit before taxes, overhead, and interest of 23 K.About Impact BioMedical Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Impact BioMedical. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Impact BioMedical based exclusively on its fundamental and basic technical indicators. By analyzing Impact BioMedical's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Impact BioMedical's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Impact BioMedical. We calculate exposure to Impact BioMedical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Impact BioMedical's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.7 M | 2.8 M | |
| Pretax Profit Margin | (0.79) | (0.83) | |
| Operating Profit Margin | 0.21 | 0.19 | |
| Net Loss | (0.79) | (0.83) |
Impact BioMedical Current Valuation Indicators
Impact BioMedical's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Impact BioMedical's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Impact BioMedical, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Impact BioMedical's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Impact BioMedical's worth.When determining whether Impact BioMedical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Impact BioMedical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Impact Biomedical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Impact Biomedical Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Impact BioMedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. To learn how to invest in Impact Stock, please use our How to Invest in Impact BioMedical guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Impact BioMedical. If investors know Impact will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Impact BioMedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Impact BioMedical is measured differently than its book value, which is the value of Impact that is recorded on the company's balance sheet. Investors also form their own opinion of Impact BioMedical's value that differs from its market value or its book value, called intrinsic value, which is Impact BioMedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Impact BioMedical's market value can be influenced by many factors that don't directly affect Impact BioMedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Impact BioMedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Impact BioMedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Impact BioMedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.